Canaccord analyst William Plovanic downgraded Merit Medical to Hold from Buy with a price target of $72, down from $73, citing valuation and his view that there is "little room to upside from current levels." He sees limited catalysts to drive a premium valuation given the company’s product set, new product pipeline and investor expectations, said Plovanic, who adds that he believes the current valuation make speculated about private equity buy-out unlikely.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on MMSI:
- Merit Medical downgraded to Hold from Buy at Canaccord
- Merit Medical management to meet with Barrington
- First Patient Enrolled in Merit Medical’s Multicenter Observational Study to Evaluate the Use of EmboCube® Embolization Gelatin to Control Bleeding or Hemorrhage
- Merit Medical enrolls first patient in EmboCube observational study
- Merit Medical launches basixALPHA Inflation Device
